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selective and strategic use of different
descending signals during different
phases of pursuit motor control (e.g.,
low-level signals may be more effec-
tive at driving the initial acceleration).
Perhaps the most striking finding in
the study is that the catch-up saccade
itself, rather than just the passage of
time during the trial, appears to be
critical for the emergence of the as-
sociation between high-level speed
judgments and the precision of post-
saccadic pursuit. Moreover, a control
experiment presented in the supple-
mentary material shows that when the
catch-up saccade is eliminated, the
association disappears. These find-
ings are puzzling, because other ex-
periments have found that saccades
are not necessary for smooth-pursuit
of high-level motion. For example,
when viewing a display containing
bidirectional apparent motion, sub-
jects experience reversals in per-
ceived motion that can be smoothly
followed with reversals in pursuit eye
velocity without making any saccades
(Madelain and Krauzlis, 2003).
One possibility is that saccades, pur-
suit, and high-level position tracking
areall supportedbycommonestimates
of target position. Given that the time
course of these estimates would likely
vary from trial to trial, the occurrence
of the targeting saccade would provide
a temporal marker for when the esti-
mate had reached a critical level, and
pursuit would be expected to show
changes at around the same time.
This explanation also predicts that the
effects observed by the authors should
not be restricted to pursuit but apply to
the saccades themselves. For exam-
ple, subjects that were more precise
in their judgments of high-level motion
would be expected to show greater
precision in the endpoints of their sac-
cades. Presumably, estimates of target
position remain available even when
saccadesarenot executed, butwithout
the temporal marker provided by sac-
cades, the effects may become too dif-
fuse to detect.
As these results illustrate, the sen-
sory-motor corner provides a unique
window into some of the core issues
in systems neuroscience. Most likely,
there are other surprising findings in
store.
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The ubiquitin-proteasome and macroautophagy-lysosome pathways are major routes for intracyto-
solic protein degradation. In many systems, proteasome inhibition is toxic. A Nature article by
Pandey et al. shows that this toxicity can be modulated by altering autophagic activity. Their
tantalizing results suggest that overexpression of HDAC6 may increase flux through the autophagy
pathway, thereby attenuating the toxicity resulting from proteasome inhibition.Intracytosolic proteins can be degraded
either by the ubiquitin-proteasome
system or by a range of lysosome-
related pathways (reviewed in Rubinsz-
tein, 2006). The ubiquitin-proteasome
pathway typically regulates levels of
short-lived proteins. These are usually854 Neuron 54, June 21, 2007 ª2007 Elsinitially tagged for degradation by link-
age of a ladder of ubiquitin molecules
to lysine residues. The ubiquitin chain
constitutes a recognition sequence
that allows them to be transported
to the proteasome, a barrel-shaped,
multiprotein, proteolytic complex. Theevier Inc.proteasome degrades the proteins
into peptides, which are further de-
graded to amino acids by cytosolic
and nuclear peptidases.
The proteasome has a narrow pore,
which precludes entrance of organ-
elles, multiprotein complexes, and
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Previewsoligomers or aggregated precursors
of the intracellular inclusions that
characterize many neurodegenerative
diseases (like polyglutamine expan-
sion diseases, including Huntington’s
disease and Kennedy’s disease).
Such structures can be degraded by
macroautophagy (which I will call
autophagy). In this pathway, cells
form double-layered vesicles around
a portion of cytosol. These autophago-
somes, which are believed to engulf
cytosolic contents in a largely unselec-
tive manner, then eventually fuse with
lysosomes, where their contents are
degraded. In addition to this form of
autophagy, there are two other auto-
phagic pathways that can deliver
substrates to the lysosome. The first,
calledmicroautophagy, involves direct
sequestration of cytosolic contents via
lysosomal membrane invagination or
septation and has only been studied
in any depth in yeast. The second
pathway, called chaperone-mediated
autophagy, involves recognition of
certain cytosolic proteins that contain
a KFERQ (or similar) pentapeptide
motif by hsc70. This then interacts
with the lysosomal membrane protein
LAMP2a, allowing direct translocation
across the lysosomal membrane.
Pandey and colleagues have re-
cently shown that proteasome inhi-
bition is toxic to Drosophila eyes
(Pandey et al., 2007). This initial result
was not unexpected—proteasome
inhibition is toxic in many settings
(e.g., Chen et al., 2005), as it leads to
the accumulation of many key mole-
cules that need to be tightly regulated
to prevent toxicity, like p53. Further-
more, global proteasome inhibition
may lead to intracellular aggregate
formation (Rideout et al., 2001). The
striking result that these authors
reported was that the toxicity resulting
from the proteasome inhibition medi-
ated by a dominant-negative protea-
some subunit was largely rescued by
overexpression of HDAC6 (and was
enhanced by HDAC6 knockdown).
HDAC6 is a member of the histone
deacetylase family. Unlike many of its
relatives, which have nuclear functions
regulating gene expression, HDAC6
is mainly found in the cytosol and
has a range of possible functions(reviewed by Boyault et al., 2006).
HDAC6 is a microtubule- and dynein-
associated protein, and microtubule-
and dynein-mediated transport of
autophagosomes are required for
delivery to lysosomes (Rubinsztein,
2006). Kopito and colleagues previ-
ously showed that HDAC6 was
required for degradation of mutant
huntingtin, an autophagy substrate
(Iwata et al., 2005). This raised the
possibility that HDAC6 may be acting
to enhance autophagy. Indeed, induc-
tion of autophagy with rapamycin also
attenuated the toxicity induced by
proteasome inhibition (Pandey et al.,
2007).
Pandey et al. went on to show in
Drosophila that overexpression of
the mutant polyglutamine-expanded
androgen receptor (modeling Ken-
nedy’s disease) in the presence of
its ligand also resulted in toxicity
associated with proteasome inhibition
and that this toxicity could also
be attenuated by overexpression of
HDAC6 (Pandey et al., 2007). This
effect of HDAC6 overexpression was
associated with enhanced turnover
of the mutant androgen receptor.
This effect was likely due to autoph-
agy, confirming previous studies that
have shown that autophagy induction
via rapamycin enhances clearance
of a range of aggregate-prone, dis-
ease-associated intracytosolic pro-
teins in cells, Drosophila and mice,
thereby attenuating their toxicities
(Ravikumar et al., 2002, 2004; Berger
et al., 2006). We previously showed
that these effects were autophagy de-
pendent in Drosophila, as no effects
of rapamycin were observed in flies
with hemizygous mutations in the
autophagy gene Atg1 (Berger et al.,
2006).
The Pandey et al. (2007) study raises
a number of tantalizing possibilities.
The first is that there is genuine cross-
talk between the ubiquitin-proteasome
and autophagy-lysosome pathways,
as autophagy induction rescued toxic-
ity caused by proteasome inhibition. It
is tempting to speculate that auto-
phagy upregulation rescued toxicity
mediated by proteasome impairment
by simply providing another route for
the clearance of the substrates thatNeuron 54ordinarily would have been removed
by the proteasome. The simplistic
expectation is that the proteasome
substrates that would be most toxic in
the presence of proteasome inhibition
would be those with the shortest half-
lives—the ubiquitin-proteasome sys-
tem is characterized by its selectivity
and the capacity to clear certain pro-
teins rapidly. By contrast, the auto-
phagy-lysosome pathway typically
clears long half-life proteins. Does this
mean that autophagy upregulation
can provide enough flux to normalize
the clearance of short-half-life proteins
that would otherwise accumulate
rapidly when the proteasome was im-
paired? This would be surprising given
the classical literature suggesting (at
least in liver) that the clearance of
short-half-life proteins is not influenced
by lysosomal inhibitors or by physio-
logical perturbations like starvation
that induce autophagy (Mortimore
and Poso, 1987).
While autophagy upregulation may
partially compensate short-lived pro-
tein degradation in the presence of
proteasomal impairment, it is possible
that the predominant protective effect
of autophagy upregulation may be
not at the level of protein clearance,
but at the level of cell death. Auto-
phagy inhibition has been shown to
sensitize cells to apoptotic insults,while
autophagy induction reduces cellular
susceptibility to subsequent apoptotic
stimuli mediated by the mitochondrial
pathway, probably because autoph-
agy reduces the mitochondrial load by
removing mitochondria (Boya et al.,
2005; Ravikumar et al., 2006). Further-
more, autophagy induction protects
Drosophila from paraquat toxicity,
possibly by the same mechanism
(Ravikumar et al., 2006). Pandey et al.
(2007) addressed this possibility in
their proteasome toxicity scenario by
showing that HDAC6 overexpression
did not rescue the rough eye pheno-
type mediated by the Drosophila cell
death protein reaper. However, it is dif-
ficult to make conclusive inferences
from this experiment, as reaper medi-
ates much of its toxicity in the cytosol
by antagonizing inhibitor of apoptosis
proteins (Kornbluth and White, 2005),
and recent data do implicate a role, June 21, 2007 ª2007 Elsevier Inc. 855
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Previewsfor mitochondrial permeabilization in
Drosophila cell death pathways (Ab-
delwahid et al., 2007). So, autophagy
induction may still be protecting
against proteasome inhibition-medi-
ated toxicity by removing some of the
mitochondria—cells can tolerate a sig-
nificant reduction in mitochondrial
load before showing effects on respi-
ration.
Another intriguing possibility sug-
gested by the paper is that pro-
teasome induction leads to a com-
pensatory increase in autophagy. This
was suggested by data reporting an
increased number of autophago-
somes in flies with proteasome inhi-
bition. These findings are consistent
with previous reports showing similar
phenomena in cell culture and in
C. elegans (Chen et al., 2005; Iwata
et al., 2005). While the idea that cells
may induce autophagy to protect
themselves in situations where the
ubiquitin-proteasome pathway is in-
hibited is appealing, there are again
other possibilities that could be
considered. Autophagosomes accu-
mulate if there is increased auto-
phagosome synthesis (where there is
generally an increase in autophagic
protein clearance), but also if there is
decreased autophagosome removal
due to impaired autophagosome-
lysosome fusion (which would result
in decreased protein clearance from
a block in the autophagic pathway). It
will be important in future studies
to discriminate between these pos-
sibilities.
This study also suggests that
HDAC6 overexpression enhances
clearance of various substrates via
autophagy. It is likely that this is how
HDAC6 is working, as it enhanced
the clearance of ligand-bound mutant
androgen receptor. Also, its overex-
pression protected against toxicity
mediated by proteasome inhibition. In
the future, it will be important to
directly test whetherHDAC6 enhances
autophagic protein clearance under
both normal conditions and in the
presence of proteasome inhibition. It
will also be interesting to know how856 Neuron 54, June 21, 2007 ª2007 ElsHDAC6 modulates autophagy and at
what stage of the process.
While the results reported byPandey
et al. (2007) are intriguing, HDAC6
overexpression/hyperactivity may not
be a straightforward therapeutic target
for polyglutamine diseases or for
autophagy upregulation. Recently,
Boyault and colleagues showed that
HDAC6 negatively regulates proteaso-
mal turnover of ubiquitinated proteins
(Boyault et al., 2006). This suggests
that HDAC6 overexpression may be
beneficial if the proteasome is signifi-
cantly impaired, but may slow turnover
of at least a subset of proteins in normal
conditions. Although Pandey et al.
(2007) show that the proteasome is
inhibited in Drosophila by ligand-
bound polyglutamine-expanded an-
drogen receptor, this phenomenon has
not been observed inmousemodels of
a number of other polyglutamine dis-
eases (reviewed in Rubinsztein, 2006).
HDAC6 also regulates other processes
relevant to at least somepolyglutamine
diseases. Saudou and colleagues re-
ported that the Huntington’s disease
mutant protein impairs the intracellular
microtubule-dependent transport of
BDNF-containing vesicles, resulting in
decreased trophic support to neurons
and increased susceptibility to cell
death. In contast to the autophagy sce-
nario, HDAC6 inhibition appears to be
beneficial in this context by increasing
tubulin acetylation, thereby increasing
the flux of BDNF-containing vesicles,
with consequent greater release of this
neurotrophin (Dompierre et al., 2007).
The Pandey et al. (2007) study raises
a number of important questions in the
context of intracellular protein degra-
dation. First, to what extent can au-
tophagy upregulation normalize turn-
over of short-lived proteins in cells
with compromised proteasome func-
tion? Second, is there an increased
production of autophagosomes (as
opposed to decreased clearance) in
cells with proteasome impairment?
Third, while their data suggest that
HDAC6 accelerates clearance of
autophagy substrates, what is/are the
underlying mechanisms involved inevier Inc.this process? Finding answers to
these questions may have relevance
for a range of neurodegenerative dis-
eases caused by aggregate-prone
intracytosolic proteins that are auto-
phagy substrates.
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